Respond: Write a letter to the editor | Write a guest opinion FRIDAY, April 28, 2017 (HealthDay News) -- Rydapt (midostaurin) has been approved by the U.S.
AML, a rapidly spreading cancer that forms in the blood marrow and spikes white blood cells, is projected to be diagnosed in just under 20,000 people, and more than 10,000 are expected to die of the disease annually, the FDA said.
Rydapt is among a class of drugs called kinase inhibitors that are designed to block enzymes that foster cancer cell growth.
Common side effects included low white cell count, fever, nausea, headache and muscular/bone pain.
A more serious side effect could include lung damage.